S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13

Haemonetics Stock Forecast, Price & News

-0.87 (-1.62%)
(As of 12/3/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
391,510 shs
Average Volume
530,941 shs
Market Capitalization
$2.70 billion
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive HAE News and Ratings via Email

Sign-up to receive the latest news and ratings for Haemonetics and its competitors with MarketBeat's FREE daily newsletter.

Haemonetics logo

About Haemonetics

Haemonetics Corp. is a global healthcare company, which engages in the development and distribution of hematology products and solutions. It operates through the following segments: Plasma, Blood Center, Hospital, and Corporate. The Plasma segment offers automated plasma collection and donor management software systems. The Blood Center segment provides solutions for donor collection centers' ability to acquire blood, filter blood, and separate blood components. The Hospital segment includes hemostasis management, cell salvage, and transfusion management services that help decision makers in hospitals optimize blood acquisition, storage, and usage in critical settings. The company was founded by Allen Latham, Jr. in 1971 and is headquartered in Boston, MA.


Haemonetics (NYSE:HAE) Issues FY 2022 Earnings Guidance
November 16, 2021 |  americanbankingnews.com
Raymond James Cuts Haemonetics (NYSE:HAE) Price Target to $70.00
November 10, 2021 |  americanbankingnews.com
JMP Securities Trims Haemonetics (NYSE:HAE) Target Price to $80.00
November 10, 2021 |  americanbankingnews.com
See More Headlines

Industry, Sector and Symbol

Surgical & medical instruments
Health Care Supplies
Year Founded

Sales & Book Value

Annual Sales
$870.46 million
Cash Flow
$3.97 per share
Book Value
$13.67 per share


Net Income
$79.47 million
Pretax Margin




Free Float
Market Cap
$2.70 billion

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Social Links


Overall MarketRank

2.26 out of 5 stars

Medical Sector

324th out of 1,388 stocks

Surgical & Medical Instruments Industry

33rd out of 126 stocks

Analyst Opinion: 3.4Community Rank: 4.1Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 1.3 5 -4 -3 -2 -1 -

Haemonetics (NYSE:HAE) Frequently Asked Questions

Is Haemonetics a buy right now?

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Haemonetics in the last twelve months. There are currently 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Haemonetics stock.
View analyst ratings for Haemonetics
or view top-rated stocks.

How has Haemonetics' stock price been impacted by Coronavirus (COVID-19)?

Haemonetics' stock was trading at $103.72 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, HAE shares have decreased by 49.1% and is now trading at $52.77.
View which stocks have been most impacted by COVID-19

When is Haemonetics' next earnings date?

Haemonetics is scheduled to release its next quarterly earnings announcement on Tuesday, February 1st 2022.
View our earnings forecast for Haemonetics

How were Haemonetics' earnings last quarter?

Haemonetics Co. (NYSE:HAE) posted its quarterly earnings results on Tuesday, November, 9th. The medical instruments supplier reported $0.60 earnings per share for the quarter, missing analysts' consensus estimates of $0.61 by $0.01. The medical instruments supplier earned $239.90 million during the quarter, compared to the consensus estimate of $240.85 million. Haemonetics had a net margin of 3.35% and a trailing twelve-month return on equity of 17.19%. The company's revenue was up 14.5% on a year-over-year basis. During the same period in the prior year, the company posted $0.62 EPS.
View Haemonetics' earnings history

What guidance has Haemonetics issued on next quarter's earnings?

Haemonetics updated its FY 2022 earnings guidance on Tuesday, November, 30th. The company provided earnings per share guidance of $2.400-$2.650 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $2.760. The company issued revenue guidance of $983.62 M-$1.02 billion, compared to the consensus revenue estimate of $1.01 billion.

What price target have analysts set for HAE?

8 brokers have issued twelve-month target prices for Haemonetics' shares. Their forecasts range from $70.00 to $86.00. On average, they expect Haemonetics' share price to reach $77.83 in the next year. This suggests a possible upside of 47.5% from the stock's current price.
View analysts' price targets for Haemonetics
or view top-rated stocks among Wall Street analysts.

Who are Haemonetics' key executives?

Haemonetics' management team includes the following people:
  • Christopher A. Simon, President, Chief Executive Officer & Director
  • William Patrick Burke, Chief Financial Officer & Executive Vice President
  • Anila Lingamneni, Chief Technology Officer & Executive VP
  • Michelle L. Basil, Secretary, Executive VP & General Counsel
  • Dan Goldstein, Vice President & Controller

What is Christopher Simon's approval rating as Haemonetics' CEO?

48 employees have rated Haemonetics CEO Christopher Simon on Glassdoor.com. Christopher Simon has an approval rating of 63% among Haemonetics' employees. This puts Christopher Simon in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Haemonetics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Haemonetics investors own include NVIDIA (NVDA), Micron Technology (MU), Johnson & Johnson (JNJ), AbbVie (ABBV), Citigroup (C), Align Technology (ALGN), (APA), Chipotle Mexican Grill (CMG), Netflix (NFLX) and Pfizer (PFE).

What is Haemonetics' stock symbol?

Haemonetics trades on the New York Stock Exchange (NYSE) under the ticker symbol "HAE."

Who are Haemonetics' major shareholders?

Haemonetics' stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (13.70%), Wellington Management Group LLP (8.31%), Neuberger Berman Group LLC (7.55%), Franklin Resources Inc. (2.90%), Janus Henderson Group PLC (2.36%) and LGT Capital Partners LTD. (2.31%). Company insiders that own Haemonetics stock include Anila Lingamneni, Christopher Simon, Dan Goldstein, Jacqueline Scanlan, Josep Llorens, Mark W Kroll, Michelle L Basil, Richard J Meelia, Stewart W Strong and William P Mr Burke.
View institutional ownership trends for Haemonetics

Which institutional investors are selling Haemonetics stock?

HAE stock was sold by a variety of institutional investors in the last quarter, including Capital Research Global Investors, Assenagon Asset Management S.A., Morgan Stanley, Renaissance Technologies LLC, Eaton Vance Management, Schroder Investment Management Group, Prosight Management LP, and Voloridge Investment Management LLC. Company insiders that have sold Haemonetics company stock in the last year include Anila Lingamneni, Christopher Simon, Dan Goldstein, Jacqueline Scanlan, Josep Llorens, Mark W Kroll, Michelle L Basil, Richard J Meelia, Stewart W Strong, and William P Mr Burke.
View insider buying and selling activity for Haemonetics
or view top insider-selling stocks.

Which institutional investors are buying Haemonetics stock?

HAE stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Wellington Management Group LLP, Janus Henderson Group PLC, Balyasny Asset Management LLC, Balyasny Asset Management LLC, Boston Trust Walden Corp, LGT Capital Partners LTD., and Two Sigma Investments LP.
View insider buying and selling activity for Haemonetics
or or view top insider-buying stocks.

How do I buy shares of Haemonetics?

Shares of HAE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Haemonetics' stock price today?

One share of HAE stock can currently be purchased for approximately $52.77.

How much money does Haemonetics make?

Haemonetics has a market capitalization of $2.70 billion and generates $870.46 million in revenue each year. The medical instruments supplier earns $79.47 million in net income (profit) each year or $0.60 on an earnings per share basis.

How many employees does Haemonetics have?

Haemonetics employs 2,708 workers across the globe.

When was Haemonetics founded?

Haemonetics was founded in 1971.

What is Haemonetics' official website?

The official website for Haemonetics is www.haemonetics.com.

Where are Haemonetics' headquarters?

Haemonetics is headquartered at 125 Summer Street, Boston MA, 02110.

How can I contact Haemonetics?

Haemonetics' mailing address is 125 Summer Street, Boston MA, 02110. The medical instruments supplier can be reached via phone at (781) 848-7100, via email at [email protected], or via fax at 781-848-5106.

This page was last updated on 12/5/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.